BioVeris Corporation, an international health care company, announced that it has introduced for sale its new M- Series M1M Analyzer at the 8th International Symposium on Protection against Chemical and Biological Warfare Agents held June 2 through 6 in Gothenburg, Sweden.

The M1M Analyzer is BioVeris' third product in its M- Series line of automated analyzers based on the company's proprietary BioVeris (BV) technology, electrochemiluminescence, and is specifically designed to function in demanding field environments, as well as in the laboratory. The M-Series product line has multiple applications and currently serves the biodefense, life science research and food testing markets.

The M1M is an automated analyzer designed for use with the company's BioVerify test kits for the detection of botulinum neurotoxins, anthrax, ricin, and staphylococcal enterotoxins A and B, among others. The analyzer has also been designed for use with the tests currently being manufactured by the company for the United States Department of Defense. The system has easy- to-use sample handling and can detect biological agents quickly and with high sensitivity. System software reports positive or negative results automatically in a standard format. The M1M Analyzer was built with specification and configuration inputs from the company's customers and is designed to meet the needs of field, mobile and centralized laboratories.

"The introduction of the M1M furthers BioVeris' commitment to enhance the safety of the civilian and armed forces populations throughout the world," said Samuel J. Wohlstadter, BioVeris' CEO. "The sensitivity and flexibility of BV technology enables us to provide products that we believe meet testing needs in the field or for use in the laboratory," he added.

The company currently provides a range of detection products and services to numerous agencies within militaries and departments of public health, including the US Department of Defense, US FDA and the Swedish Defense Research Agency.